心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

重视动脉粥样硬化性心血管疾病合并静脉血栓栓塞症的抗栓治疗——2021美国心脏病学会抗栓决策路径专家共识解读

2022-03-24 中国医学科学院北京协和医学院国家心血管病中心阜外医院呼吸与肺血管疾病诊治中心 中国循环杂志

动脉粥样硬化性心血管疾病静脉血栓栓塞症

抗血小板治疗是动脉粥样硬化性心血管疾病（ASCVD）抗栓治疗的主要手段，而抗凝治疗是静脉血栓栓塞症（VTE）和心房颤动抗栓治疗的必由之路。在临床上，抗血小板治疗与抗凝治疗常联合应用，然而联合抗栓治疗的

中文标题：

重视动脉粥样硬化性心血管疾病合并静脉血栓栓塞症的抗栓治疗——2021美国心脏病学会抗栓决策路径专家共识解读

发布机构：

中国医学科学院北京协和医学院国家心血管病中心阜外医院呼吸与肺血管疾病诊治中心

发布日期：

2022-03-24

简要介绍：

抗血小板治疗是动脉粥样硬化性心血管疾病（ASCVD）抗栓治疗的主要手段，而抗凝治疗是静脉血栓栓塞症（VTE）和心房颤动抗栓治疗的必由之路。在临床上，抗血小板治疗与抗凝治疗常联合应用，然而联合抗栓治疗的出血发生风险显著增加，需仔细平衡出血与血栓栓塞的发生风险。目前，ASCVD合并心房颤动的抗栓治疗方案已得到深入研究并不断更新完善。目前仍然缺乏ASCVD合并VTE抗栓治疗的循证医学证据，2021年美国心脏病学会发布了抗栓决策路径专家共识，针对ASCVD合并VTE的抗栓治疗路径和方案提出了合理化建议，对于指导临床实践具有重要意义。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=重视动脉粥样硬化性心血管疾病合并静脉血栓栓塞症的抗栓治疗——2021美国心脏病学会抗栓决策路径专家共识解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=380a41c002a03329, title=重视动脉粥样硬化性心血管疾病合并静脉血栓栓塞症的抗栓治疗——2021美国心脏病学会抗栓决策路径专家共识解读, enTitle=, guiderFrom=中国循环杂志, authorId=0, author=, summary=抗血小板治疗是动脉粥样硬化性心血管疾病（ASCVD）抗栓治疗的主要手段，而抗凝治疗是静脉血栓栓塞症（VTE）和心房颤动抗栓治疗的必由之路。在临床上，抗血小板治疗与抗凝治疗常联合应用，然而联合抗栓治疗的, cover=https://img.medsci.cn/202242/1648889133258_5579292.png, journalId=0, articlesId=null, associationId=2596, associationName=中国医学科学院北京协和医学院国家心血管病中心阜外医院呼吸与肺血管疾病诊治中心, associationIntro=中国医学科学院北京协和医学院国家心血管病中心阜外医院呼吸与肺血管疾病诊治中心, copyright=0, guiderPublishedTime=Thu Mar 24 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">抗血小板治疗是动脉粥样硬化性心血管疾病（ASCVD）抗栓治疗的主要手段，而抗凝治疗是静脉血栓栓塞症（VTE）和心房颤动抗栓治疗的必由之路。在临床上，抗血小板治疗与抗凝治疗常联合应用，然而联合抗栓治疗的出血发生风险显著增加，需仔细平衡出血与血栓栓塞的发生风险。目前，ASCVD合并心房颤动的抗栓治疗方案已得到深入研究并不断更新完善。目前仍然缺乏ASCVD合并VTE抗栓治疗的循证医学证据，2021年美国心脏病学会发布了抗栓决策路径专家共识，针对ASCVD合并VTE的抗栓治疗路径和方案提出了合理化建议，对于指导临床实践具有重要意义。&nbsp;</span></p>, tagList=[TagDto(tagId=16145, tagName=动脉粥样硬化性心血管疾病), TagDto(tagId=57456, tagName=静脉血栓栓塞症)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3081, appHits=219, showAppHits=0, pcHits=569, showPcHits=2861, likes=1, shares=50, comments=4, approvalStatus=1, publishedTime=Sun Apr 03 15:43:00 CST 2022, publishedTimeString=2022-03-24, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Apr 02 16:47:21 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Thu Jan 04 14:44:01 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=重视动脉粥样硬化性心血管疾病合并静脉血栓栓塞症的抗栓治疗——2021美国心脏病学会抗栓决策路径专家共识解读.pdf)])
重视动脉粥样硬化性心血管疾病合并静脉血栓栓塞症的抗栓治疗——2021美国心脏病学会抗栓决策路径专家共识解读.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214788, encodeId=b0811214e88d9, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:09:09 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208501, encodeId=99ed1208501ff, content=真的不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Apr 04 09:55:32 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208498, encodeId=90d0120849850, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ff5497451, createdName=蓝莓兔子, createdTime=Mon Apr 04 09:46:33 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208477, encodeId=8ff412084e74e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Mon Apr 04 08:00:53 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
    2022-04-26 su_yi_fei

    实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1214788, encodeId=b0811214e88d9, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:09:09 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208501, encodeId=99ed1208501ff, content=真的不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Apr 04 09:55:32 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208498, encodeId=90d0120849850, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ff5497451, createdName=蓝莓兔子, createdTime=Mon Apr 04 09:46:33 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208477, encodeId=8ff412084e74e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Mon Apr 04 08:00:53 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
    2022-04-04 ms3000000876072209

    真的不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214788, encodeId=b0811214e88d9, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:09:09 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208501, encodeId=99ed1208501ff, content=真的不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Apr 04 09:55:32 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208498, encodeId=90d0120849850, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ff5497451, createdName=蓝莓兔子, createdTime=Mon Apr 04 09:46:33 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208477, encodeId=8ff412084e74e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Mon Apr 04 08:00:53 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
    2022-04-04 蓝莓兔子

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1214788, encodeId=b0811214e88d9, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:09:09 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208501, encodeId=99ed1208501ff, content=真的不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Apr 04 09:55:32 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208498, encodeId=90d0120849850, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ff5497451, createdName=蓝莓兔子, createdTime=Mon Apr 04 09:46:33 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208477, encodeId=8ff412084e74e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Mon Apr 04 08:00:53 CST 2022, time=2022-04-04, status=1, ipAttribution=)]
    2022-04-04 ms3000000376140643

    学习学习

    0

相关指南

2022 ASPC临床实践声明：动脉粥样硬化性心血管疾病的风险评估

美国心脏病预防学会(ASPC,American Society for Preventive Cardiology) · 2022-03-15

2022 ASPC临床实践声明：减少动脉粥样硬化性心血管疾病的营养改善方法

美国心脏病预防学会(ASPC,American Society for Preventive Cardiology) · 2022-03-02

2022 SIIA共识文件：固定的降低高胆固醇水平的组合策略作为治疗高胆固醇血症和高／极高心血管风险高血压患者治疗的第一步

意大利高血压学会(SIIA,Italian Society of Hypertension) · 2022-01-03

欧洲心脏病学会心血管疾病预防质量指标：由心血管疾病预防质量指标工作组与欧洲心脏病学会欧洲预防心脏病学会合作制定

欧洲心脏病学会(ESC,European Society of Cardiology) · 2021-09-23

超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2020-04-30

2020 EAS共识声明：低密度脂蛋白导致的动脉粥样硬化性心血管疾病的病理生理学、遗传学和治疗见解

欧洲动脉硬化学会(EAS,European Atherosclerosis Society) · 2020-02-13